Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer

Carcinogenesis

Volumn 29, Issue 7, 2008, Pages 1312-1318

  Maruyama, Reo ^a   Akino, Kimishige ^a   Toyota, Minoru ^a   Suzuki, Hiromu ^a   Imai, Takashi ^a   Ohe Toyota, Mutsumi ^a   Yamamoto, Eiichiro ^a   Nojima, Masanori ^a   Fujikane, Tomoko ^a   Sasaki, Yasushi ^a   Yamashita, Toshiharu ^a   Watanabe, Yoshiyuki ^a,b   Hiratsuka, Hiroyoshi ^a   Hirata, Koichi ^a   Itoh, Fumio ^b   Imai, Kohzoh ^a   Shinomura, Yasuhisa ^a   Tokino, Takashi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CHEMOKINE; COMPLEMENTARY DNA; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 18; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN MST1; PROTEIN MST2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 2A; RAS PROTEIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CELL STRUCTURE; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; CYTOPLASM; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; STOMACH CANCER;

AMINO ACID SEQUENCE; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTOPLASM; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 49349109183     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn060     Document Type: Article

References (50)

1. Neugut,A.I. et al. (1996) Epidemiology of gastric cancer. Semin. Oncol., 23, 281-291.
2. Nanus,D.M. et al. (1990) Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology, 98, 955-960.
3. Strickler,J.G. et al. (1994) p53 mutations and microsatellite instability in sporadic gastric cancer: When guardians fail. Cancer Res., 54, 4750-4755.
4. Satoh,A. et al. (2002) DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br. J. Cancer, 86, 1817-1823.
5. Satoh,A. et al. (2003) Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res. 63, 8606-8613.
6. Suzuki,H. et al. (2000) Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res., 60, 4353-4357.
7. Yoshiura,K. et al. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl Acad. Sci. USA, 92, 7416-7419.
8. Akino,K. et al. (2007) Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci., 98, 88-95.
9. Kaneda,A. et al. (2002) Identification of silencing of nine genes in human gastric cancers. Cancer Res., 62, 6645-6650.
10. Maekita,T. et al. (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res., 12, 989-995.
11. Malumbres,M. et al. (2003) RAS oncogenes: The first 30 years. Nat. Rev. Cancer, 3, 459-465.
12. Rajagopalan,H. et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418, 934.
13. Tuveson,D.A. et al. (2003) BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell, 4, 95-98.
14. Kim,I.J. et al. (2003) Mutational analysis of BRAF and K-ras in gastric cancers: Absence of BRAF mutations in gastric cancers. Hum. Genet., 114, 118-120.
15. Dammann,R. et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25, 315-319.
16. Dammann,R. et al. (2001) Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61, 3105-3109.
17. Akino,K. et al. (2005) The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 129, 156-169.
18. Allen,N.P. et al. (2007) RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene, 26, 6203-6211.
19. Eckfeld,K. et al. (2004) RASSF4/AD037 is a potential ras effector/ tumor suppressor of the RASSF family. Cancer Res., 64, 8688-8693.
20. Endoh,M. et al. (2005) RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br. J. Cancer, 93, 1395-1399.
21. Falvella,F.S. et al. (2006) Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene, 25, 3934-3938.
22. Hesson,L.B. et al. (2005) CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene, 24, 3987-3994.
23. Kaira,K. et al. (2007) Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int. J. Oncol., 31, 169-173.
24. Tommasi,S. et al. (2002) RASSF3 and NORE 1: Identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene, 21, 2713-2720.
25. Zhang,Z. et al. (2007) Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int. J. Cancer, 120, 32-38.
26. Avruch,J. et al. (2005) Norel and RASSFI regulation of cell proliferation and of the MST1/2 kinases. Meth. Enzymol., 407 290-310.
27. Feig,L.A. et al. (2002) Cell signaling: Life or death decisions of ras proteins. Curr. Biol., 12, R259-R261.
28. Seidel,C. et al. (2007) Frequent hypermethylation of MST1 and MST2 in soft fissue sarcoma. Mol. Carcinog, 46, 865-871.
29. Yanagihara,K. et al. (1991) Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res., 51, 381-386.
30. Yanagihara,K. et al. (1993) Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res., 53, 5815-5821.
31. Kusano,M. et al. (2006) Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer, 106. 1467-1479.
32. Clark,S.J. et al. (1994) High sensitivity mapping of Methylated cytosines. Nucleic Acids Res., 22, 2990-2997.
33. Konishi,K. et al. (2007) Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasim. Gastroenterology, 132 1254-1260.
34. Yang,A.S. et al. (2004) A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res., 32, e38.
35. Ishida,S. et al. (2000) Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn. J. Cancer Res., 91, 174-180.
36. Sasaki,Y et al. (2001) Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces cell cycle arrest and apoptosis in colorectal cancer cell lines: Potential application to gene therapy of colorectal cancer. Gene Ther., 8, 1401-1408.
37. Weber,M. et al. (2007) Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet., 39, 457-466.
38. Hocker,M. et al. (1998) Oxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells. J. Biol. Chem., 273, 23046-23054.
39. Zhu,Y. et al. (2005) Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. Oncogene, 24, 3886-3895.
40. Lee,J.W. et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res., 12, 57-61.
41. Park,J.B. et al. (1989) Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res., 49, 6605-6609.
42. Pfeifer,G.P. et al. (2005) Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc.), 70, 576-583.
43. Etienne-Manneville,S. et al. (2002) Rho GTPases in cell biology. Nature, 420, 629-635.
44. Kuntzen,C. et al. (2005) Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res., 65, 6780-6788.
45. Sparmann,A. et al. (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458.
46. Strieter,R.M. et al. (2004) CXC chemokines. in angiogenesis of cancer. Semin. Cancer Biol., 14, 195-200.
47. Rubie,C. et al. (2006) Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol., 27, 166-174.
48. Yan,L. et al. (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem.. 276. 37258-37265.
49. Etoh,T. et al. (2004) Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am. J. Pathol., 164, 689-699.
50. Tsai,C.L. et al. (2006) Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 66, 11668-11676.